Tricuspid valve regurgitation can be managed with medications for symptom relief or surgery to replace or repair the valve. However, for some patients, the operative risks were high and the condition was left largely untreated.

With the advancement and availability of less invasive transcatheter valve therapies, such as the TriClip and TricValve, selected patients who are unsuitable for open heart surgery might be able to get their condition treated. Although these are relatively new procedures for which long-term data on outcomes are still being studied, they are additional options for patients with significant symptoms who are deemed unsuitable for surgery.